**How Will International Reference Pricing Affect You?**

*International reference pricing* is a form of government price setting in which U.S. bureaucrats could determine the value of our medicines based on how foreign governments and politicians value these treatments and cures. Not only does international reference pricing allow foreign politicians to decide what your medicines are worth and what diseases are worth investing in, but it lets policies set by foreign politicians influence how our government makes decisions for American patients.

By outsourcing decision making about the value of our medicines, international reference pricing could create risks for American patients.

- **Long delays & reduced access to lifesaving medicines**
- **Fewer new treatments & cures in the future**
- **Weaker U.S. leadership in biopharmaceutical innovation**

The numbers from countries where international reference pricing is used speak for themselves. In countries where the government sets prices, patients have much less access to new medicines.

**Percent of new cancer medicines available**

- **United States**: 96%
- **Canada**: 59%
- **France**: 67%
- **Ireland**: 53%
- **Italy**: 58%

**Average delay in availability of new cancer medicines**

- **14 months** (Canada)
- **16 months** (France)
- **21 months** (Italy)
- **23 months** (Ireland)

The consequences of international reference pricing take on an even greater meaning as some policymakers have proposed looking to the judgments of foreign bureaucrats when deciding what American medicines are worth.

Now more than ever, we need policies that foster American innovation and help usher in the treatments and vaccines the world is waiting for. There are better solutions that would deliver real savings for Americans at the pharmacy counter without sacrificing innovation and American leadership.

**Policymakers should protect U.S. innovation and make sure Americans don’t have to rely on other countries to decide the value of treatments. Don’t jeopardize American patients’ access to today’s medicines and tomorrow’s cures.**

Learn more at PhRMA.org